Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEC96719 in NASH – Phase II
CTR20211428Phase 2Completed
- Sponsor
- Guangdong Dongyangguang Pharmaceutical
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hec96719 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by Guangdong Dongyangguang Pharmaceutical. Started Jul 2021; status: completed.
02
Drugs
hec96719
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20211428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211428.